These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23638650)

  • 21. QT dispersion in HIV-infected patients receiving combined antiretroviral therapy.
    Wongcharoen W; Suaklin S; Tantisirivit N; Phrommintikul A; Chattipakorn N
    Ann Noninvasive Electrocardiol; 2014 Nov; 19(6):561-6. PubMed ID: 24750179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and significance of an isolated long QT interval in elite athletes.
    Basavarajaiah S; Wilson M; Whyte G; Shah A; Behr E; Sharma S
    Eur Heart J; 2007 Dec; 28(23):2944-9. PubMed ID: 17947213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval-Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection.
    Tamraz B; Reisner L; French AL; King ST; Fischl MA; Ofotokun I; Kashuba A; Milam J; Murphy K; Augenbraun M; Liu C; Finley PR; Aouizerat B; Cocohoba J; Gange S; Bacchetti P; Greenblatt RM
    Pharmacotherapy; 2019 Sep; 39(9):899-911. PubMed ID: 31332819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more.
    Nogueras M; Navarro G; Antón E; Sala M; Cervantes M; Amengual M; Segura F
    BMC Infect Dis; 2006 Nov; 6():159. PubMed ID: 17087819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients.
    Chinello P; Lisena FP; Angeletti C; Boumis E; Papetti F; Petrosillo N
    J Infect; 2007 Jun; 54(6):597-602. PubMed ID: 17174400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with initiation of prolonged analgesic use among patients in the HIV Outpatient Study (HOPS).
    Koeppe J; Lichtenstein K; Armon C; Chmiel JS; Buchacz K; Wood K; Brooks JT;
    Clin J Pain; 2011 Oct; 27(8):699-706. PubMed ID: 21540742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment.
    Grande I; Pons A; Baeza I; Torras Á; Bernardo M
    Hum Psychopharmacol; 2011 Aug; 26(6):397-403. PubMed ID: 21826738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.